Novavax COVID-19 Vaccine 89.3% Effective In Phase 3 UK Trial
Published
Biotech company Novavax, Inc. (NVAX), Thursday announced that its COVID-19 vaccine NVX-CoV2373 was 89.3% effective against the coronavirus in its Phase 3 clinical trial conducted in the UK.
Full Article